Advanced search
Publication Cover
Biomarkers in Medicine Volume 4, 2010 - Issue 4
Submit an article Journal homepage
166
Views
0
CrossRef citations to date
0
Altmetric
Review

YKL-40: A New Biomarker in Cardiovascular Disease?

Anders Bruun MathiasenCardiac Catheterization Laboratory 2014,The Heart Centre,Rigshospitalet,Copenhagen University Hospital and Faculty of Health Sciences,Blegdamsvej 9, DK-2100 Copenhagen,Denmark.
,
Kristoffer Mads Aaris HenningsenCardiac Catheterization Laboratory 2014,The Heart Centre,Rigshospitalet,Copenhagen University Hospital and Faculty of Health Sciences,Blegdamsvej 9, DK-2100 Copenhagen,Denmark.
,
Marina Jurjevna HarutyunyanCardiac Catheterization Laboratory 2014,The Heart Centre,Rigshospitalet,Copenhagen University Hospital and Faculty of Health Sciences,Blegdamsvej 9, DK-2100 Copenhagen,Denmark.
,
Naja Dam MygindCardiac Catheterization Laboratory 2014,The Heart Centre,Rigshospitalet,Copenhagen University Hospital and Faculty of Health Sciences,Blegdamsvej 9, DK-2100 Copenhagen,Denmark.
&
Jens KastrupCardiac Catheterization Laboratory 2014,The Heart Centre,Rigshospitalet,Copenhagen University Hospital and Faculty of Health Sciences,Blegdamsvej 9, DK-2100 Copenhagen,Denmark.Correspondence[email protected]
Pages 591-600 | Published online: 11 Aug 2010

Bibliography

  • Yusuf S , ReddyS, OunpuuS, AnandS: Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.Circulation104(22) , 2746–2753 (2001).
  • Yusuf S , ReddyS, OunpuuS, AnandS: Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies.Circulation104(23) , 2855–2864 (2001).
  • Hansson GK : Inflammation, atherosclerosis, and coronary artery disease.N. Engl. J. Med.352(16) , 1685–1695 (2005).
  • Ross R : Atherosclerosis – an inflammatory disease.N. Engl. J. Med.340(2) , 115–126 (1999).
  • Koenig W , LowelH, BaumertJ, MeisingerC: C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.Circulation109(11) , 1349–1353 (2004).
  • Luc G , BardJM, Juhan-VagueI yeet al.: C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study.Arterioscler. Thromb. Vasc. Biol.23(7) , 1255–1261 (2003).
  • Mueller C , BuettnerHJ, HodgsonJMet al.: Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients.Circulation105(12) , 1412–1415 (2002).
  • Ridker PM , StampferMJ, RifaiN: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.JAMA285(19) , 2481–2485 (2001).
  • Kistorp C , RaymondI, PedersenF, GustafssonF, FaberJ, HildebrandtP: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.JAMA293(13) , 1609–1616 (2005).
  • Olsen MH , HansenTW, ChristensenMKet al.: N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.Eur. Heart J.28(11) , 1374–1381 (2007).
  • Olsen MH , SehestedtT, LyngbaekSet al.: Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide – three new cardiovascular risk markers – do they improve risk prediction and influence treatment?Curr. Vasc. Pharmacol.8(1) , 134–139 (2010).
  • Arnlov J , EvansJC, MeigsJBet al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study.Circulation112(7) , 969–975 (2005).
  • Borch-Johnsen K , Feldt-RasmussenB, StrandgaardS, SchrollM, JensenJS: Urinary albumin excretion. An independent predictor of ischemic heart disease.Arterioscler. Thromb. Vasc. Biol.19(8) , 1992–1997 (1999).
  • Morrow DA , de Lemos JA: Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation115(8) , 949–952 (2007).
  • Johansen JS : Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.Dan. Med. Bull.53(2) , 172–209 (2006).
  • Johansen JS , WilliamsonMK, RiceJS, PricePA: Identification of proteins secreted by human osteoblastic cells in culture.J. Bone Miner. Res.7(5) , 501–512 (1992).
  • Hakala BE , WhiteC, ReckliesAD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family.J. Biol. Chem.268(34) , 25803–25810 (1993).
  • Morrison BW , LederP: neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.Oncogene9(12) , 3417–3426 (1994).
  • Shackelton LM , MannDM, MillisAJ: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling.J. Biol. Chem.270(22) , 13076–13083 (1995).
  • Rehli M , KrauseSW, AndreesenR: Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation.Genomics43(2) , 221–225 (1997).
  • Harvey S , WeismanM, O‘DellJet al.: Chondrex: new marker of joint disease.Clin. Chem.44(3) , 509–516 (1998).
  • Mohanty AK , SinghG, ParamasivamMet al.: Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution.J. Biol. Chem.278(16) , 14451–14460 (2003).
  • Malinda KM , PonceL, KleinmanHK, ShackeltonLM, MillisAJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells.Exp. Cell. Res.250(1) , 168–173 (1999).
  • Nishikawa KC , MillisAJ: gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells.Exp. Cell. Res.287(1) , 79–87 (2003).
  • Recklies AD , WhiteC, LingH: The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signaling pathways.Biochem. J.365(Pt 1) , 119–126 (2002).
  • Ling H , ReckliesAD: The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-α.Biochem. J.380(Pt 3) , 651–659 (2004).
  • Swirski FK , LibbyP, AikawaEet al.: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata.J. Clin. Invest.117(1) , 195–205 (2007).
  • Libby P , BraunwaldE: Braunwald‘s Heart Disease (8th Edition). A Textbook of Cardiovascular Medicine.Saunders/Elsevier,PA, USA (2008).
  • Baeten D , BootsAM, SteenbakkersPGet al.: Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis.Arthritis Rheum.43(6) , 1233–1243 (2000).
  • Kirkpatrick RB , MaticoRE, McNultyDE, StricklerJE, RosenbergM: An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages.Gene153(2) , 147–154 (1995).
  • Krause SW , RehliM, KreutzM, SchwarzfischerL, PaulauskisJD, AndreesenR: Differential screening identifies genetic markers of monocyte to macrophage maturation.J. Leukoc. Biol.60(4) , 540–545 (1996).
  • Rehli M , NillerHH, AmmonCet al. : Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation.J. Biol. Chem.278(45) , 44058–44067 (2003).
  • Boot RG ,vanAchterberg TA,vanAken BEet al.: Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.Arterioscler. Thromb. Vasc. Biol.19(3) , 687–694 (1999).
  • Cintin C , JohansenJS, ChristensenIJ, PricePA, SorensenS, NielsenHJ: Serum YKL-40 and colorectal cancer.Br. J. Cancer79(9–10) , 1494–1499 (1999).
  • Cintin C , JohansenJS, ChristensenIJ, PricePA, SorensenS, NielsenHJ: High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.Cancer95(2) , 267–274 (2002).
  • Johansen JS , DrivsholmL, PricePA, ChristensenIJ: High serum YKL-40 level in patients with small cell lung cancer is related to early death.Lung Cancer46(3) , 333–340 (2004).
  • Bi J , LauSH, LvZLet al. : Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.Hum. Pathol.40(12) , 1790–1797 (2009).
  • Schmidt H , JohansenJS, GehlJ, GeertsenPF, FodeK,vonder MH: Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.Cancer106(5) , 1130–1139 (2006).
  • Daugaard S , ChristensenLH, HogdallE: Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2–40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.APMIS117(7) , 518–525 (2009).
  • Biggar RJ , JohansenJS, SmedbyKEet al. : Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.Clin. Cancer Res.14(21) , 6974–6978 (2008).
  • Mitsuhashi A , MatsuiH, UsuiHet al. : Serum YKL-40 as a marker for cervical adenocarcinoma.Ann. Oncol.20(1) , 71–77 (2009).
  • Mylin AK , RasmussenT, JohansenJSet al. : Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.Eur. J. Haematol.77(5) , 416–424 (2006).
  • Bergmann OJ , JohansenJS, KlausenTWet al. : High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.Clin. Cancer Res.11(24 Pt 1) , 8644–8652 (2005).
  • Jensen BV , JohansenJS, PricePA: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.Clin. Cancer Res.9(12) , 4423–4434 (2003).
  • Yamac D , OzturkB, CoskunUet al.: Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.Adv. Ther.25(8) , 801–809 (2008).
  • Dupont J , TanwarMK, ThalerHTet al.: Early detection and prognosis of ovarian cancer using serum YKL-40.J. Clin. Oncol.22(16) , 3330–3339 (2004).
  • Hogdall EV , RingsholtM, HogdallCKet al.: YKL-40 tissue expression and plasma levels in patients with ovarian cancer.BMC Cancer9(8) , 8 (2009).
  • Yang GF , CaiPY, LiXM, DengHX, HeWP, XieD: Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues.Chin. J. Cancer28(2) , 142–145 (2009).
  • Kucur M , IsmanFK, BalciCet al. : Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.Urol. Oncol.26(1) , 47–52 (2008).
  • Johansen JS , BojesenSE, MylinAK, Frikke-SchmidtR, PricePA, NordestgaardBG: Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population.J. Clin. Oncol.27(4) , 572–578 (2009).
  • Shao R , HamelK, PetersenLet al. : YKL-40, a secreted glycoprotein, promotes tumor angiogenesis.Oncogene28(50) , 4456–4468 (2009).
  • Volck B , JohansenJS, StoltenbergMet al. : Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology.Osteoarthritis Cartilage9(3) , 203–214 (2001).
  • Johansen JS , StoltenbergM, HansenMet al.: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity.Rheumatol. (Oxf.)38(7) , 618–626 (1999).
  • Johansen JS , KirwanJR, PricePA, SharifM: Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction.Scand. J. Rheumatol.30(5) , 297–304 (2001).
  • Matsumoto T , TsurumotoT: Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters.Clin. Exp. Rheumatol.19(6) , 655–660 (2001).
  • Peltomaa R , PaimelaL, HarveyS, HelveT, Leirisalo-RepoM: Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity.Rheumatol. Int.20(5) , 192–196 (2001).
  • Zivanovic S , RackovLP, VojvodicD, VuceticD: Human cartilage glycoprotein 39 – biomarker of joint damage in knee osteoarthritis.Int. Orthop.33(4) , 1165–1170 (2009).
  • Koutroubakis IE , PetinakiE, DimouliosPet al. : Increased serum levels of YKL-40 in patients with inflammatory bowel disease.Int. J. Colorectal Dis.18(3) ,254–259 (2003).
  • Vind I , JohansenJS, PricePA, MunkholmP: Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease.Scand. J. Gastroenterol.38(6) , 599–605 (2003).
  • Myasoedova E , GabrielSE: Cardiovascular disease in rheumatoid arthritis: a step forward.Curr. Opin. Rheumatol.22(3) , 342–347 (2010).
  • Chupp GL , LeeCG, JarjourNet al. : A chitinase-like protein in the lung and circulation of patients with severe asthma.N. Engl. J. Med.357(20) , 2016–2027 (2007).
  • Ober C , TanZ, SunYet al. : Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function.N. Engl. J. Med.358(16) , 1682–1691 (2008).
  • Rathcke CN , HolmkvistJ, HusmoenLLet al. : Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults.PLoS One4(7) , E6106 (2009).
  • Hempen M , KoppHP, ElhenickyMet al. : YKL-40 is elevated in morbidly obese patients and declines after weight loss.Obes. Surg.19(11) , 1557–1563 (2009).
  • Nielsen AR , ErikstrupC, JohansenJSet al. : Plasma YKL-40: a BMI-independent marker of Type 2 diabetes.Diabetes57(11) , 3078–3082 (2008).
  • Rathcke CN , JohansenJS, VestergaardH: YKL-40, a biomarker of inflammation, is elevated in patients with Type 2 diabetes and is related to insulin resistance.Inflamm. Res.55(2) , 53–59 (2006).
  • Rathcke CN , PerssonF, TarnowL, RossingP, VestergaardH: YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with Type 1 diabetes and increases with levels of albuminuria.Diabetes Care32(2) , 323–328 (2009).
  • Gustafson B , GoggS, HedjazifarS, JenndahlL, HammarstedtA, SmithU: Inflammation and impaired adipogenesis in hypertrophic obesity in man.Am. J. Physiol. Endocrinol. Metab. DOI:10.1152/ajpendo.00377.2009 (2009) (Epub ahead of print).
  • Spalding KL , ArnerE, WestermarkPOet al.: Dynamics of fat cell turnover in humans.Nature453(7196) , 783–787 (2008).
  • Andersson CX , GustafsonB, HammarstedtA, HedjazifarS, SmithU: Inflamed adipose tissue, insulin resistance and vascular injury.Diabetes Metab. Res. Rev.24(8) , 595–603 (2008).
  • Mathieu P , LemieuxI, DespresJP: Obesity, inflammation, and cardiovascular risk.Clin. Pharmacol. Ther.87(4) , 407–416 (2010).
  • Johansen JS , KrabbeKS, MollerK, PedersenBK: Circulating YKL-40 levels during human endotoxaemia.Clin. Exp. Immunol.140(2) , 343–348 (2005).
  • Kronborg G , OstergaardC, WeisNet al. : Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease.Scand. J. Infect. Dis.34(5) , 323–326 (2002).
  • Hattori N , OdaS, SadahiroTet al. : YKL-40 identified by proteomic analysis as a biomarker of sepsis.Shock32(4) , 393–400 (2009).
  • Ostergaard C , JohansenJS, BenfieldT, PricePA, LundgrenJD: YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis.Clin. Diagn. Lab. Immunol.9(3) , 598–604 (2002).
  • Nojgaard C , HostNB, ChristensenIJet al. : Serum levels of YKL-40 increases in patients with acute myocardial infarction.Coron. Artery Dis.19(4) , 257–263 (2008).
  • Wang Y , RipaRS, JohansenJSet al. : YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease.Scand. Cardiovasc. J.42(5) , 295–302 (2008).
  • Hedegaard A , SejerstenRR, JohansenJS, JorgensenE, KastrupJ: Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction.Scand. J. Clin. Lab. Invest.70(2) , 80–86 (2010).
  • Hogdall EV , JohansenJS, KjaerSK, PricePA, BlaakjaerJ, HogdallCK: Stability of YKL-40 concentration in blood samples.Scand. J. Clin. Lab. Invest.60(4) , 247–251 (2000).
  • Johansen JS , JensenHS, PricePA: A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid.Br. J. Rheumatol.32(11) , 949–955 (1993).
  • Johansen JS , HvolrisJ, HansenM, BackerV, LorenzenI, PricePA: Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint.Br. J. Rheumatol.35(6) , 553–559 (1996).
  • Garnero P , PipernoM, GineytsE, ChristgauS, DelmasPD, VignonE: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.Ann. Rheum. Dis.60(6) , 619–626 (2001).
  • Kastrup J , JohansenJS, WinkelPet al.: High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.Eur. Heart J.30(9) , 1066–1072 (2009).
  • Kucur M , IsmanFK, KaradagB, VuralVA, TavsanogluS: Serum YKL-40 levels in patients with coronary artery disease.Coron. Artery Dis.18(5) , 391–396 (2007).
  • Rathcke CN , RaymondI, KistorpC, HildebrandtP, FaberJ, VestergaardH: Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population.Int. J. Cardiol.143(1) , 35–42 (2009).
  • Zheng JL , LuL, HuJet al. : Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.Atherosclerosis210(2) , 590–595 (2010).
  • Rathcke CN , KistorpC, RaymondIet al. : Plasma YKL-40 levels are elevated in patients with chronic heart failure.Scand. Cardiovasc. J.44(2) , 92–99 (2010).
  • Baigent C , KeechA, KearneyPMet al. : Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet366(9493) , 1267–1278 (2005).
  • Scirica BM , MorrowDA: Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out.Circulation113(17) , 2128–2134 (2006).
  • Bonnet J , McPhersonR, TedguiAet al. : Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.Clin. Ther.30(12) , 2298–2313 (2008).
  • Frustaci A , ChimentiC, BellocciF, MorganteE, RussoMA, MaseriA: Histological substrate of atrial biopsies in patients with lone atrial fibrillation.Circulation96(4) , 1180–1184 (1997).
  • Wijffels MC , KirchhofCJ, DorlandR, AllessieMA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.Circulation92(7) , 1954–1968 (1995).
  • Chung MK , MartinDO, SprecherDet al. : C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation.Circulation104(24) , 2886–2891 (2001).
  • Engelmann MD , SvendsenJH: Inflammation in the genesis and perpetuation of atrial fibrillation.Eur. Heart J.26(20) , 2083–2092 (2005).
  • Henningsen KM , NilssonB, BruunsgaardH, ChenX, PedersenBK, SvendsenJH: Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation.Scand. Cardiovasc. J.1–7 (2008).
  • Kallergis EM , ManiosEG, KanoupakisEMet al.: The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation.Heart94(2) , 200–204 (2008).
  • Loricchio ML , CianfroccaC, PasceriVet al. : Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.Am. J. Cardiol.99(10) , 1421–1424 (2007).
  • Watanabe E , ArakawaT, UchiyamaT, KodamaI, HishidaH: High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion.Int. J. Cardiol.108(3) , 346–353 (2006).
  • Henningsen KM , TherkelsenSK, JohansenJS, BruunsgaardH, SvendsenJH: Plasma YKL-40, a new biomarker for atrial fibrillation?Europace11(8) , 1032–1036 (2009).
  • Henningsen KM , NilssonB, JohansenJ, ChenX, PehrsonS, SvendsenJH: Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.Inflamm. Res.59(6) , 463–439 (2010).
  • Johansen JS , LottenburgerT, NielsenHJet al. : Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.Cancer Epidemiol. Biomarkers Prev.17(10) , 2603–2608 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.